TY - JOUR
T1 - Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer
T2 - an international multicenter study of 395 patients
AU - Lehrer, Eric J.
AU - Khosla, Atulya A.
AU - Ozair, Ahmad
AU - Gurewitz, Jason
AU - Bernstein, Kenneth
AU - Kondziolka, Douglas
AU - Niranjan, Ajay
AU - Wei, Zhishuo
AU - Lunsford, L. Dade
AU - Mathieu, David
AU - Trudel, Claire
AU - Deibert, Christopher P.
AU - Malouff, Timothy D.
AU - Ruiz-Garcia, Henry
AU - Peterson, Jennifer L.
AU - Patel, Samir
AU - Bonney, Phillip
AU - Hwang, Lindsay
AU - Yu, Cheng
AU - Zada, Gabriel
AU - Picozzi, Piero
AU - Franzini, Andrea
AU - Attuati, Luca
AU - Prasad, Rahul N.
AU - Raval, Raju R.
AU - Palmer, Joshua D.
AU - Lee, Cheng chia
AU - Yang, Huai che
AU - Fakhoury, Kareem R.
AU - Rusthoven, Chad G.
AU - Dickstein, Daniel R.
AU - Sheehan, Jason P.
AU - Trifiletti, Daniel M.
AU - Ahluwalia, Manmeet S.
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2023/10
Y1 - 2023/10
N2 - Purpose: Approximately 80% of brain metastases originate from non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICI) and stereotactic radiosurgery (SRS) are frequently utilized in this setting. However, concerns remain regarding the risk of radiation necrosis (RN) when SRS and ICI are administered concurrently. Methods: A retrospective study was conducted through the International Radiosurgery Research Foundation. Logistic regression models and competing risks analyses were utilized to identify predictors of any grade RN and symptomatic RN (SRN). Results: The study included 395 patients with 2,540 brain metastases treated with single fraction SRS and ICI across 11 institutions in four countries with a median follow-up of 14.2 months. The median age was 67 years. The median margin SRS dose was 19 Gy; 36.5% of patients had a V12 Gy ≥ 10 cm3. On multivariable analysis, V12 Gy ≥ 10 cm3 was a significant predictor of developing any grade RN (OR: 2.18) and SRN (OR: 3.95). At 1-year, the cumulative incidence of any grade and SRN for all patients was 4.8% and 3.8%, respectively. For concurrent and non-concurrent groups, the cumulative incidence of any grade RN was 3.8% versus 5.3%, respectively (p = 0.35); and for SRN was 3.8% vs. 3.6%, respectively (p = 0.95). Conclusion: The risk of any grade RN and symptomatic RN following single fraction SRS and ICI for NSCLC brain metastases increases as V12 Gy exceeds 10 cm3. Concurrent ICI and SRS do not appear to increase this risk. Radiosurgical planning techniques should aim to minimize V12 Gy.
AB - Purpose: Approximately 80% of brain metastases originate from non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICI) and stereotactic radiosurgery (SRS) are frequently utilized in this setting. However, concerns remain regarding the risk of radiation necrosis (RN) when SRS and ICI are administered concurrently. Methods: A retrospective study was conducted through the International Radiosurgery Research Foundation. Logistic regression models and competing risks analyses were utilized to identify predictors of any grade RN and symptomatic RN (SRN). Results: The study included 395 patients with 2,540 brain metastases treated with single fraction SRS and ICI across 11 institutions in four countries with a median follow-up of 14.2 months. The median age was 67 years. The median margin SRS dose was 19 Gy; 36.5% of patients had a V12 Gy ≥ 10 cm3. On multivariable analysis, V12 Gy ≥ 10 cm3 was a significant predictor of developing any grade RN (OR: 2.18) and SRN (OR: 3.95). At 1-year, the cumulative incidence of any grade and SRN for all patients was 4.8% and 3.8%, respectively. For concurrent and non-concurrent groups, the cumulative incidence of any grade RN was 3.8% versus 5.3%, respectively (p = 0.35); and for SRN was 3.8% vs. 3.6%, respectively (p = 0.95). Conclusion: The risk of any grade RN and symptomatic RN following single fraction SRS and ICI for NSCLC brain metastases increases as V12 Gy exceeds 10 cm3. Concurrent ICI and SRS do not appear to increase this risk. Radiosurgical planning techniques should aim to minimize V12 Gy.
KW - Brain neoplasms
KW - Combined modality therapy
KW - Immune checkpoint inhibitors
KW - Non-small cell lung cancer
KW - Radiation injuries
KW - Radiosurgery
UR - http://www.scopus.com/inward/record.url?scp=85175073477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85175073477&partnerID=8YFLogxK
U2 - 10.1007/s11060-023-04413-4
DO - 10.1007/s11060-023-04413-4
M3 - Article
C2 - 37889444
AN - SCOPUS:85175073477
SN - 0167-594X
VL - 165
SP - 63
EP - 77
JO - Journal of neuro-oncology
JF - Journal of neuro-oncology
IS - 1
ER -